12:00 AM
 | 
Dec 09, 2002
 |  BioCentury  |  Tools & Techniques

Prolysis: In bacteria veritas

Last week's deal with chemistry company Evotec OAI AG will help Prolysis Ltd. leverage its bacterial high throughput screening technology to elbow its way into drug discovery. Prolysis, which was spun out of Oxford University in 1998, uses in vivo bacterial assays to discover new antimicrobial compounds.

Prolysis (Oxford, U.K.) has developed bacterial high throughput screening assays covering five key cellular processes. "We have assays for cell division, DNA replication, chromosome segregation, DNA supercoiling and RNA transcription," said Lloyd Czaplewski, director of research.

The cell division assays are...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >